Donald Santel

Donald J.
Santel was the founder of CoTherix, Inc. since 2000, serving as Chief Executive Officer & Director from 2000 to 2007.
Current jobs include Chairman at Tentarix Biotherapeutics LP since 2022, Chairman at Ocelot Bio, Inc. since 2021, and Director at Inograft Biotherapeutics, Inc. since 2023.
Former jobs include President, Chief Executive Officer & Director at Hyperion Therapeutics, Inc. from 2009 to 2015, Executive Chairman at Adicet Therapeutics, Inc. from 2019 to 2020, Chairman at NeuroRecovery Technologies, Inc., Non-Executive Chairman at Oyster Point Pharma, Inc. from 2021 to 2023, Independent Director at Anthera Pharmaceuticals, Inc. from 2011 to 2012, Director at Arête Therapeutics, Inc., Independent Non-Executive Director at ChemGenex Pharmaceuticals Pty Ltd. in 2009, Director at ChemGenex Pharmaceuticals, Inc., Director at Abilitech Medical, Inc., Independent Director at Consonance-HFW Acquisition Corp.
from 2020 to 2021, Independent Director at Jade Biosciences, Inc. from 2023 to 2025, Principal at Medtronic, Inc. from 1982 to 1991, Vice President-Marketing & International Sales at Cardiac Pathways Corp.
from 1992 to 1997, General Manager at CardioVasc, Inc. in 1998, and Principal at Reflow, Inc. in 2000.
Education includes an undergraduate degree from Purdue University and a graduate degree from the University of Minnesota.